PL:NYSEPlanet Labs PBC Analysis
Data as of 2026-06-26 - not real-time
$26.51
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Planet Labs (PL) trades below its short‑term moving average while still remaining above the long‑term trend line, indicating a neutral price stance. The Relative Strength Index sits in the low‑30s, hinting at oversold conditions, yet the MACD shows a bearish histogram, suggesting downward momentum. Recent earnings delivered a modest revenue beat but a sizable earnings miss, while the company announced a new high‑resolution satellite shipment and secured additional multi‑million dollar contracts with the National Geospatial‑Intelligence Agency, reinforcing its growth narrative. Despite a rapid 40%+ year‑over‑year revenue expansion and a substantial backlog, profitability remains elusive, margins are negative, and the forward price‑to‑earnings ratio is astronomically high. The DCF‑derived fair value is far below the current market price, flagging a significant overvaluation. Combined with extreme short‑term volatility and a beta above two, the stock presents a high‑risk, high‑potential profile that may appeal to long‑term growth investors but warrants caution for shorter horizons.
Investors should weigh the upside from expanding government contracts and satellite deployments against the steep valuation gap and ongoing cash‑burn.
Investors should weigh the upside from expanding government contracts and satellite deployments against the steep valuation gap and ongoing cash‑burn.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Earnings miss and negative EPS
- Bearish MACD momentum
- Oversold RSI suggesting possible short‑term bounce
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong revenue growth and expanding backlog
- New satellite launch and additional NGA contracts
- Continued overvaluation relative to DCF fair value
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- High‑growth satellite data market and recurring government revenue
- Potential for margin improvement as scale increases
- Strategic positioning in daily global imagery and AI‑enabled analytics
Key Metrics & Analysis
Financial Health
Revenue Growth42.10%
Profit Margin-111.17%
P/E Ratio7961.0
ROE-83.98%
ROA-5.87%
Debt/Equity109.99
P/B Ratio21.3
Op. Cash Flow$132.5M
Free Cash Flow$84.9M
Industry P/E32.0
Technical Analysis
TrendNeutral
RSI32.2
Support$25.30
Resistance$51.76
MA 20$35.06
MA 50$37.81
MA 200$24.26
MACDBearish
VolumeDecreasing
Fear & Greed Index87.7
Valuation
Fair Value$9.36
Target Price$39.80
Upside/Downside50.13%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.42
Volatility117.82%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.